Ucgun Nil Irem, Zeki Fikret Cenk, Sahin Hamurcu Mualla
Department of Ophthalmology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
Department of Ophthalmology, Ankara City Hospital, Ankara, Turkey.
Curr Stem Cell Res Ther. 2025;20(4):421-433. doi: 10.2174/011574888X293265240311120103.
To determine the effectiveness of bone marrow-derived mesenchymal stem cell therapy on visual acuity and visual field in patients with retinitis pigmentosa.
Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field.
Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared.
Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p < 0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014).
Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period.
确定骨髓间充质干细胞疗法对视网膜色素变性患者视力和视野的有效性。
视网膜色素变性的干细胞治疗可改善视力和视野。
本研究纳入了27例诊断为视网膜色素变性患者的47只眼。通过深层巩膜下注射给予异体骨髓间充质干细胞。在治疗前以及治疗后第1、3和6个月对所有患者进行全面的常规眼科检查、光学相干断层扫描（蔡司，Cirrus HD-OCT）测量和视野（Humphrey视野计，30-2）测试。患者的最佳矫正视力通过Snellen视力表确定并转换为logMAR。对患者治疗前和治疗后第6个月进行视觉诱发电位（VEP）和视网膜电图（ERG）检查（Metrovision），比较数据。
治疗前视力为0.74±0.49 logMAR，治疗后为0.61±0.46 logMAR。视力有统计学显著提高（p<0.001）。发现治疗前视野偏差为-27.16±5.77 dB，治疗后为-26.59±5.96 dB（p = 0.005）。治疗前神经节细胞层为46.26±12.87μm，治疗后为52.47±12.26μm（p = 0.003）。与治疗前（4.43±2.42μV）和治疗后（5.09±2.86μV）相比，图形VEP 120º P100波幅有显著改善（p = 0.013）。暗视0.01时ERG潜伏期测量治疗前为18.33±15.39μV，治疗后为20.87±18.64μV（p = 0.02）。暗视3.0时ERG潜伏期测量治疗前为20.75±26.31μV，治疗后为23.10±28.60μV（p = 0.014）。
视网膜色素变性是一种进行性遗传性疾病，可导致严重视力丧失。在视网膜色素变性中，通过深层巩膜下注射应用骨髓间充质干细胞对视觉功能有积极影响。在6个月的随访期内未在患者中检测到全身或眼部副作用。
